News | Ventricular Assist Devices (VAD) | April 03, 2017

New Protocol at Henry Ford Hospital Dramatically Increases Heart Attack Survival Rates

Analysis of more than 15,000 heart attack patients finds hospitals achieved survival rates up to 75 percent with implantation of Impella pump before any other intervention

Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study

April 3, 2017 — Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing rapid hemodynamic support before treating the cause of a heart attack, according to a new analysis that included more than 15,000 patients across the United States.

Doctors in Detroit increased survival rates from 50 percent to 84 percent by following a protocol developed using a straw-sized heart pump, said cardiologist William W. O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital.

“This shows that if you can apply these best practices systematically, you can dramatically increase survival in cardiogenic shock,” said O’Neill, who presented the analysis at the American College of Cardiology’s Scientific Sessions, March 17-19 in Washington, D.C., offering to train other centers in the life-saving approach. “We believe the protocol can benefit patients nationwide.”

Watch a VIDEO interview with O'Neill at ACC.17  - "Cardiogenic Shock Supported With Impella Shows Good Outcomes."

Cardiogenic shock is a complication of heart attacks that affects approximately 5-8 percent of patients in the United States annually. In these patients, the pump function of the heart is severely depressed, causing low blood pressure and vital organs to be deprived of sufficient blood supply. Despite contemporary treatments, an average of about 50 percent of patients experiencing the condition die.

The analysis looked at the use of the Impella, a straw-sized pump approved by the U.S. Food and Drug Administration (FDA) in 2008 and specifically for treatment of cardiogenic shock in 2016. The pump is inserted through a catheter in the groin and into the heart to keep blood pumping throughout the body. Doctors use it while they are treating the cause of a heart attack, either by inserting a stent, removing a clot or taking other necessary action while the tiny pump supports circulation.

Watch the VIDEO "Demonstration of the Impella Percutaneous Hemodynamic Support Device."

The analysis retroactively looked at data collected by Abiomed, the pump’s manufacturer, in 15,529 patients – 72 percent men and an average age of 63 – treated between 2009 and 2017.

The investigators noticed that survival rates in patients treated with the Impella pump fluctuated wildly by hospital, O’Neill said. A third of hospitals experienced a 25 percent survival rate; a third, 50 percent survival; and a third, 75 percent.

“There was a huge variation in outcomes between the centers, between the lowest performing and highest performing centers,” said O’Neill. “It looked as though putting the Impella in soon, before you do anything else, is connected to survival.”

Inserting the pump first ensures the patient’s other vital organs are supported, buying time for cardiologists to open the blocked arteries to restore natural blood flow. The hospitals with high survival rates also used less inotropes and correctly sized catheters to monitor heart pressure, O’Neill added.

To test the best practices, O’Neill organized five hospital systems in southeast Michigan to follow a specific protocol in ST-elevation myocardial infarction (STEMI) patients who showed signs of cardiogenic shock between July 2016 and Jan. 2017. Of the 37 patients supported with the Detroit Cardiogenic Shock Initiative protocol, 31 (84 percent) survived.

“Some of these breakthroughs are so straightforward, you wonder, why didn’t we think of it before?” said O’Neill. “We believe this approach can benefit patients nationwide.”

Participants with Henry Ford Health System in the Detroit Cardiogenic Shock Initiative include Beaumont Hospital, Detroit Medical Center, Ascension’s St. John and Providence hospitals and Saint Joseph Mercy Health System. 

“Cardiologists have been trying to move the needle on heart attack survival rate for years; this is a huge success,” said Thomas Lalonde, M.D., chief of cardiology at St. John Hospital in Detroit.

Key to the protocol is medical personnel recognizing cardiogenic shock in patients as soon as possible, O’Neill added.

“If they think the patient needs medication to raise the blood pressure, that’s when they should be thinking, ‘Get them someplace where they can get a pump implanted,’” said O’Neill, who intends to help other hospital systems across the United States implement the protocols.

Read about another cariogenic shock study presented at ACC.17, “Study Examines Influence of Cardiac Arrest and Cardiogenic Shock on STEMI Patient Outcomes.”
 

The the article “Collaboration by Metro Detroit Cardiologists Increases Cardiogenic Shock Survival Rate.”

For more information: www.henryford.com/cardiogenicshock

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init